Personalized GLP-1 Dosing Through Compounding: When Custom Strengths Help

Brand-name Wegovy comes in five fixed dose strengths: 0.25 mg, 0.5 mg, 1.0 mg, 1.7 mg, and 2.4 mg. Ozempic offers 0.25 mg, 0.5 mg, 1.0 mg, and 2.0 mg. These are the steps Novo Nordisk chose for their clinical trial protocols, and they work well for most patients. But "most" is not "all" — and for patients who don't fit neatly into the standard titration ladder, compounding pharmacies can prepare doses that brand-name products cannot.

When Standard Doses Don't Fit

Sensitivity-Driven Slower Titration

The jump from 0.25 mg to 0.5 mg — a doubling of the dose — is the steepest percentage increase in the standard titration schedule. Some patients tolerate 0.25 mg well but experience significant nausea at 0.5 mg. For these patients, a compounded intermediate dose of 0.375 mg can provide a gentler step-up that maintains the titration trajectory without the side-effect spike.

Similarly, the jump from 1.0 mg to 1.7 mg (a 70% increase) and from 1.7 mg to 2.4 mg (a 41% increase) can be difficult for sensitive patients. Compounded intermediate strengths — 1.25 mg, 1.5 mg, 2.0 mg — allow prescribers to create gentler titration curves that keep patients progressing rather than stalling at a dose they can't tolerate.

Weight-Adjusted Maintenance

Not every patient needs the maximum dose. Some reach their clinical goals — weight loss target, A1C target, or symptom resolution — at doses below the standard maintenance level. A patient maintaining well on 1.0 mg doesn't need to titrate to 2.4 mg just because the protocol says so. But what about a patient who maintains at something between standard steps — say, 1.25 mg or 0.75 mg? Compounding makes those precision maintenance doses possible.

Dose-Reduction Tapering

When patients discontinue a GLP-1, the standard approach is to simply stop. But some prescribers prefer a gradual taper — stepping down through decreasing doses over several weeks to minimize rebound appetite and weight regain. Compounding allows for custom tapering steps (e.g., 2.4 → 2.0 → 1.5 → 1.0 → 0.5 → stop) that aren't available with fixed-dose brand-name products.

The Clinical Rationale

Personalized dosing is not about giving patients whatever they want — it's about matching the pharmacological response to the individual patient's needs and tolerability. The clinical rationale rests on several well-established principles:

• Dose-response variability: Individual patients respond differently to the same dose based on body weight, metabolic rate, receptor density, and genetic factors. A fixed dose schedule optimizes for the population average, not the individual.
• Side effect management: GLP-1 side effects (nausea, vomiting, constipation) are dose-dependent. Finer titration control allows prescribers to find each patient's threshold — the highest effective dose that stays below the side-effect ceiling.
• Adherence optimization: Patients who tolerate their dose are more likely to continue treatment. Patients who suffer significant side effects at each dose escalation are more likely to abandon treatment prematurely. Gentler titration may improve long-term adherence even if it takes longer to reach the target dose.

How Compounding Pharmacies Create Custom Doses

Creating a non-standard dose strength is straightforward for a compounding pharmacy. The pharmacist adjusts the concentration of semaglutide in the solution — for example, instead of the standard 5 mg/mL vial, preparing a 2.5 mg/mL vial that allows finer dose graduation with standard insulin syringe volumes. Or, more commonly, the pharmacy prepares a vial at a standard concentration and the prescriber adjusts the injection volume to achieve the desired dose.

The key quality considerations for custom doses are the same as for any compounded preparation: accurate weighing, precise dilution, verified potency, and proper labeling. A 0.375 mg dose requires the same pharmacy quality controls as a 2.4 mg dose — the compounding standards don't relax because the amount is smaller.

What This Does Not Mean

Personalized dosing through compounding is not:

• Self-adjusting your dose: Any dose change — standard or custom — should be directed by a prescriber who's monitoring your response, side effects, and lab values.
• An excuse for underdosing: Some budget providers label their vials as "custom low dose" to justify putting less API in the vial. That's a cost-cutting measure, not personalized medicine.
• Superior to standard titration: For the majority of patients, the FDA-reviewed titration schedules work well. Custom dosing is a tool for exceptions, not the default.

Providers That Offer Flexible Dosing Options